Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

NCT07362199 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia
Treatment

Interventions

DRUG: Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）

Sponsor

Institute of Hematology & Blood Diseases Hospital, China